Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune®, which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

**CORPORATE OVERVIEW**

Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.

Founded and led for more than 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, pain and rare diseases.

**GENERAL COMPANY INFORMATION**

- Founded in 1988: Publicly traded company (NASDAQ: REGN) since 1991
- More than 7,500 employees in the U.S. and EU
- Current annualized R&D spending in excess of $2 billion; partially supported through research collaborations

**LOCATIONS**

- Tarrytown, NY: Corporate and Research & Development headquarters
- Rensselaer, NY and Limerick, Ireland: Large-scale biologics Industrial Operations and Product Supply (IOPS) facilities
- Sleepy Hollow, NY and Basking Ridge, NJ: Satellite offices
- Dublin, Ireland and London, UK: EU business offices

**LEADERSHIP TEAM**

- **Leonard S. Schleifer, MD, PhD**
  Founder, President and Chief Executive Officer
- **George D. Yancopoulos, MD, PhD**
  Founding Scientist, President and Chief Scientific Officer
  + Member, National Academy of Sciences
- **P. Roy Vagelos, MD**
  Chairman of the Board
  + Former Chief Executive Officer and Chairman of the Board, Merck & Co.
  + Member, National Academy of Sciences
- **Board of Directors** includes two Nobel Laureates and seven members of the National Academy of Sciences

**FDA-APPROVED & MARKETED MEDICINES**

- **Arcalyst® (rilorexacet)** Injection for Subcutaneous Use
- **Dupixent® (dupilumab) Injection**
  200mg - 300mg
- **Eylea® (aflibercept) Injection**
  For Intravitreal Injection
- **Kezara® (sarilumab) Injection**
  150mg - 200mg
  Please see Full Prescribing Information including Boxed WARNING at www.kezara.com
- **Praluent® (alirocumab) Injection**
  75mg/110mg/420mg
- **Libtayo® (cemiplimab-rwlc)** Injection 350mg

*U.S. Food and Drug Administration.
### LEADERS IN TECHNOLOGY

- **Fully human monoclonal antibodies**: Regeneron has developed a suite of patented technologies (VelociSuite®), including VelociGene®, VelociImmune® and VelociMab®, that allow Regeneron scientists to determine the best targets for therapeutic intervention and rapidly generate high quality, fully human antibodies as drug candidates.

- **Fusion proteins**: Our novel and patented “Trap” fusion protein technology creates high-affinity product candidates for many different types of signaling molecules, including growth factors and cytokines. The technology involves fusing two distinct fully human receptor components and a fully human immunoglobulin.

- **Regeneron Genetics Center**: A large-scale, fully-integrated genomics program that uses DNA sequencing and analysis to better understand the causes of disease, and to more rapidly and efficiently bring new therapeutics to patients in need.

---

<table>
<thead>
<tr>
<th>IMMUNOLOGY &amp; INFLAMMATORY DISEASES</th>
<th>CARDIOVASCULAR/ METABOLIC DISEASES</th>
<th>ONCOLOGY</th>
<th>INFECTIOUS DISEASES</th>
<th>OPHTHALMOLOGY</th>
<th>PAIN</th>
<th>RARE DISEASES</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CEMIPLIMAB</strong> PD-1 Antibody</td>
<td>Cancer</td>
<td><strong>CEMIPLIMAB</strong> PD-1 Antibody</td>
<td>Basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (CSCC)</td>
<td><strong>GARETOSMAB</strong></td>
<td>Activin A Antibody</td>
<td>Fibroblast growth factor (FGF)</td>
</tr>
<tr>
<td><strong>REGN1979</strong> CD20 X CD3 Antibody</td>
<td>Cancer</td>
<td><strong>REGN1979</strong> CD20 X CD3 Antibody</td>
<td>Relapsed/refractory follicular lymphoma</td>
<td><strong>POZELIMAB</strong> C5 Antibody</td>
<td>Neonatal hemoglobinuria</td>
<td><strong>POZELIMAB</strong> C5 Antibody</td>
</tr>
<tr>
<td><strong>REGN3787</strong> LAG-3 Antibody</td>
<td>Cancer</td>
<td><strong>REGN3787</strong> LAG-3 Antibody</td>
<td><strong>POZELIMAB</strong> C5 Antibody</td>
<td><strong>FASINUMAB</strong></td>
<td>NGF Antibody</td>
<td>Chronic pain from osteoarthritis of the knee or hip</td>
</tr>
<tr>
<td><strong>REGN4018</strong> MUC16 X CD3 Antibody</td>
<td>Cancer</td>
<td><strong>REGN4018</strong> MUC16 X CD3 Antibody</td>
<td><strong>POZELIMAB</strong> C5 Antibody</td>
<td><strong>LAPUIMAB</strong></td>
<td>IL-33 Antibody</td>
<td>Articular and systemic arthritis</td>
</tr>
<tr>
<td><strong>REGN4659</strong> CTLA4 Antibody</td>
<td>Cancer</td>
<td><strong>REGN4659</strong> CTLA4 Antibody</td>
<td><strong>POZELIMAB</strong> C5 Antibody</td>
<td><strong>REGN4018</strong></td>
<td>MUC16 X CD3 Antibody</td>
<td><strong>REGN4018</strong></td>
</tr>
<tr>
<td><strong>REGN5458</strong> BCMA X CD3 Antibody</td>
<td>Cancer</td>
<td><strong>REGN5458</strong> BCMA X CD3 Antibody</td>
<td><strong>POZELIMAB</strong> C5 Antibody</td>
<td><strong>REGN4018</strong></td>
<td>MUC16 X CD3 Antibody</td>
<td><strong>REGN4018</strong></td>
</tr>
<tr>
<td><strong>REGN3048-3051</strong> Middle Eastern Respiratory Coronavirus Antibody</td>
<td>MERS-CoV infection</td>
<td><strong>REGN3048-3051</strong> Middle Eastern Respiratory Coronavirus Antibody</td>
<td><strong>POZELIMAB</strong> C5 Antibody</td>
<td><strong>REGN4018</strong></td>
<td>MUC16 X CD3 Antibody</td>
<td><strong>REGN4018</strong></td>
</tr>
<tr>
<td><strong>REGN4461</strong> LEPR Antibody</td>
<td>Lipodystrophy and obesity</td>
<td><strong>REGN4461</strong> LEPR Antibody</td>
<td><strong>POZELIMAB</strong> C5 Antibody</td>
<td><strong>REGN4018</strong></td>
<td>MUC16 X CD3 Antibody</td>
<td><strong>REGN4018</strong></td>
</tr>
<tr>
<td><strong>REGN5713-5714-5715</strong> Betv1 Antibody</td>
<td>Birch allergy</td>
<td><strong>REGN5713-5714-5715</strong> Betv1 Antibody</td>
<td><strong>POZELIMAB</strong> C5 Antibody</td>
<td><strong>REGN4018</strong></td>
<td>MUC16 X CD3 Antibody</td>
<td><strong>REGN4018</strong></td>
</tr>
</tbody>
</table>

This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.

---

### Fast Company: Best Workplaces for Innovators, 2019
Shingo Institute: The Shingo Prize, 2019
Fortune: 100 Best Companies to Work For, 2019
Science: #1 Top Employer, 2018
Civic 50: Most Community-Minded Companies, 2018

Forbes: World’s Most Innovative Companies, 2018
Great Places to Work: Best Workplace in Ireland, 2018
MIT Technology Review: Top 10 Smartest Companies, 2017
Barron’s: World’s Best CEOs, 2016

To learn more about us, please visit:

REGENERON.COM  
@REGENERON

Science to Medicine, VelociGene, VelociSuite, VelocImmune, VelociMab, ARCALYST and EYLEA are registered trademarks of Regeneron Pharmaceuticals, Inc. in the U.S.; Praluent, Dupixent and Kevzara are registered trademarks of Sanofi.
© 2019 Regeneron Pharmaceuticals, Inc. 8/19